UpdatesGeneral Updates
Strides Pharma reported 13% YoY revenue growth to ₹1,265.4 Cr, driven by strong 17% growth in Ex-US markets.
Strides Pharma Science LimitedSTAR · Filed with the exchange
EBITDA rose 5.4% to ₹229.8 Cr.
Operational PAT hit ₹123.1 Cr.
The company also reduced net debt by ₹11.9 Cr and divested Pivot Path, unlocking ₹100 Cr.
No comments yet. Be the first.